report error
Found 3 records.
Displayed records from 1 to 3
|
1. (CSDB ID: 12675) | report error |
| -3)-a-L-Rhap-(1-4)-a-L-FucpNAc-(1-3)-b-D-GlcpNAc-(1- | Show graphically |
|
Show legend Show as text |
Escherichia coli O26
(NCBI TaxID 404399,
species name lookup)
]
gsu.eduBacterial pathogen infections are fast-growing public health threats and worldwide problems. Glycoconjugate vaccines are among the most effective means in combating such infections. Recent advances in bacterial protein glycan coupling technology (PGCT) have revolutionized the production of glycoconjugate vaccines and drawn enormous attention from both researchers and pharmaceutical companies. Cloning of bacterial surface polysaccharide gene cluster is a prerequisite for the application of PGCT. In this study, we applied the RecET direct cloning strategy for rapid and efficient cloning of O-antigen polysaccharide gene clusters from Escherichia coli serotypes O25b, O26, and O55 in a high-fidelity manner. Then, these gene clusters were applied in PGCT to produce corresponding glycoconjugates. Subsequent immunological studies verified the abilities of glycoconjugate vaccine candidates O25-maltose-binding protein (MBP), O26-MBP, and O55-MBP to generate serotype-specific antibodies and confer protection against E. coli infections. The combination of RecET direct cloning and PGCT makes the rapid production of glycoconjugate vaccines against fast-expanding bacterial pathogens possible.
glycoengineering, glycoconjugate vaccine, bacterial surface polysaccharide gene cluster, PGCT, RecET direct cloning
Structure type: polymer chemical repeating unit|
2. (CSDB ID: 12676) | report error |
| a-Colp-(1-2)-b-D-Galp-(1-3)-+ | -6)-b-D-GlcpNAc-(1-3)-a-D-Galp-(1-3)-b-D-GalpNAc-(1- | Show graphically |
|
Show legend Show as text |
Escherichia coli O55
(NCBI TaxID 2170726,
species name lookup)
]gsu.eduBacterial pathogen infections are fast-growing public health threats and worldwide problems. Glycoconjugate vaccines are among the most effective means in combating such infections. Recent advances in bacterial protein glycan coupling technology (PGCT) have revolutionized the production of glycoconjugate vaccines and drawn enormous attention from both researchers and pharmaceutical companies. Cloning of bacterial surface polysaccharide gene cluster is a prerequisite for the application of PGCT. In this study, we applied the RecET direct cloning strategy for rapid and efficient cloning of O-antigen polysaccharide gene clusters from Escherichia coli serotypes O25b, O26, and O55 in a high-fidelity manner. Then, these gene clusters were applied in PGCT to produce corresponding glycoconjugates. Subsequent immunological studies verified the abilities of glycoconjugate vaccine candidates O25-maltose-binding protein (MBP), O26-MBP, and O55-MBP to generate serotype-specific antibodies and confer protection against E. coli infections. The combination of RecET direct cloning and PGCT makes the rapid production of glycoconjugate vaccines against fast-expanding bacterial pathogens possible.
glycoengineering, glycoconjugate vaccine, bacterial surface polysaccharide gene cluster, PGCT, RecET direct cloning
Structure type: suggested polymer biological repeating unit|
3. (CSDB ID: 12942) | report error |
| a-L-Rhap-(1-3)-+ | -4)-a-D-Glcp-(1-3)-a-L-FucpNAc-(1-3)-b-D-GlcpNAc-(1- | b-D-Glcp-(1-6)-+ | Show graphically |
|
Show legend Show as text |
Escherichia coli O25b
(Ancestor NCBI TaxID 1095709,
species name lookup)
]gsu.eduBacterial pathogen infections are fast-growing public health threats and worldwide problems. Glycoconjugate vaccines are among the most effective means in combating such infections. Recent advances in bacterial protein glycan coupling technology (PGCT) have revolutionized the production of glycoconjugate vaccines and drawn enormous attention from both researchers and pharmaceutical companies. Cloning of bacterial surface polysaccharide gene cluster is a prerequisite for the application of PGCT. In this study, we applied the RecET direct cloning strategy for rapid and efficient cloning of O-antigen polysaccharide gene clusters from Escherichia coli serotypes O25b, O26, and O55 in a high-fidelity manner. Then, these gene clusters were applied in PGCT to produce corresponding glycoconjugates. Subsequent immunological studies verified the abilities of glycoconjugate vaccine candidates O25-maltose-binding protein (MBP), O26-MBP, and O55-MBP to generate serotype-specific antibodies and confer protection against E. coli infections. The combination of RecET direct cloning and PGCT makes the rapid production of glycoconjugate vaccines against fast-expanding bacterial pathogens possible.
glycoengineering, glycoconjugate vaccine, bacterial surface polysaccharide gene cluster, PGCT, RecET direct cloning
Structure type: polymer chemical repeating unit| New query | Export IDs | Home | Help |
Execution: 8 sec